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Yarrowia lipolyticaamphipathic compounds including several detergents are known to inhibit the
ubiquinone reductase reaction of respiratory chain complex I (proton pumping NADH:ubiquinone oxidor-
eductase). Guided by the X-ray structure of the peripheral arm of complex I from Thermus thermophiluswe have
generated a large collection of site-directed mutants in the yeast Yarrowia lipolytica targeting the proposed
ubiquinone and inhibitor binding pocket of this huge multiprotein complex at the interface of the 49-kDa and
PSST subunits. We could identify a number of residues where mutations changed I50 values for representatives
from all three groups of hydrophobic inhibitors.Manymutations around the domain of the 49-kDa subunit that is
homologous to the [NiFe] centre binding region of hydrogenase conferred resistance to DQA (class I/type A) and
rotenone (class II/type B) indicating a wider overlap of the binding sites for these two types of inhibitors. In
contrast, a region near iron–sulfur cluster N2, where the binding of the n-alkyl-polyoxyethylene-ether detergent
C12E8 (type C) was exclusively affected, appeared comparably well separated. Taken together, our data provide
structure-based support for the presence of distinct but overlapping binding sites for hydrophobic inhibitors
possibly extending into the ubiquinone reduction site of mitochondrial complex I.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
Respiratory chain complex I is the largest enzyme complex of the
inner mitochondrial or bacterial plasma membrane. It couples the
transfer of two electrons from NADH to ubiquinone to the translocation
of four protons across the bioenergetic membrane [1]. In the strictly
aerobic yeast Yarrowia lipolytica complex I is composed of at least 40
different subunits with a total molecular mass of 947 kDa [22]. Electron
microscopic single particle analysis of complex I from Y. lipolytica [2]
revealed that like complex I from other organisms, the enzyme is L-
shaped with a hydrophobic membrane embedded arm and a hydro-
philic peripheral arm extending into the mitochondrial matrix.
A large number of hydrophobic and amphipathic compounds,
including natural products, synthetic compounds and even some
commonly used detergents like Triton X-100 and n-alkyl-polyoxyethy-
lene-ethers are known to inhibit the ubiquinone reductase reaction of
complex I [3–7]. Several classiﬁcation schemes have been proposed fornzyl)-4-(p-tert-butylphenoxy)
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ll rights reserved.this plethora of inhibitors that were mostly based on their behaviour in
steady-state inhibition kinetics. In a study using bovine heart SMP and
ubiquinone-2 as a substrate Friedrich et al. proposed two inhibitor
classes that differed in enzyme speciﬁcity andmode of action [8]: class I
inhibitors, exempliﬁed by the natural compound piericidin A inhibit
complex I in a partially competitive manner and are also competitive
inhibitors of glucose:ubiquinone oxidoreductase from Gluconobacter
oxidans. Class II inhibitors, exempliﬁed by the natural compound
rotenone, act on complex I in a non-competitive manner and are
ineffective on bacterial glucose:ubiquinone oxidoreductase.
Another somewhat more hypothetical classiﬁcation by Degli Esposti
that was based on an extensive literature survey postulates three
functionally different typesof complex I inhibitorswith typeA inhibitors
acting as antagonists of the substrate ubiquinone, type B inhibitors
acting to displace the intermediate ubisemiquinone and type C
inhibitors acting as antagonists of the product ubiquinol [9]. Type A
and type B inhibitors in most cases correspond to class I and class II
inhibitors, respectively. Type C inhibitors, exempliﬁed by the capsaicins
and their synthetic analogues like CC44 [10], form a third distinct class.
The n-alkyl-polyoxyethylene-ether detergent Thesit (C12E9) was shown
to competewith the capsaicinoid CC44 andwas thus classiﬁed as a type
C inhibitor [7]. In contrast to capsaicin and its derivatives, polyoxyethy-
lene-ether detergents also inhibit complex I from Y. lipolytica.
Initially, it had been suggested that the various types or classes of
complex I inhibitors would bind to at least two discrete domains [8,9].
However it was demonstrated by direct competition binding assays
that representatives from all inhibitor classes bind to partially
Table 1
Effects of point mutations introduced into the 49-kDa subunit
Strain Complex I
contenta
Complex I
activityb
Apparent
Km for
DBQ
I50
C12E8 DQA Rotenone
% % µM µM nM
Parental 100±3e 100±5e 15e 3.3 16e 530e
R141A 130c 17c 10f n.d. 21c 570c
R141K 140d 45d 13d 3.4 55d 1500d
D143A 118±3 30±3 18 2.8 180 10,000
D143C 97±2 73±4 13 2.7 30c 580c
D143E 112±4 69±6 14 3.1 38c 630c
D143N 91±3 42±5 15 2.5 60 5000
S146C 100g 100g 12g 3.4 80g 1500g
S146V 94±4 94±6 16 3.2 29 1100
M188C 98±3 104±6 18 3.0 28 2500
M188L 102±2 120±5 23 2.9 16 780
F203E 97±3 28±3 14 2.8 70 2300
F203W 103±3 98±6 15 0.8 14 450
F207H 117±4 92±8 15 5.0 45 3000
F207W 99±2e 58±2e 12e 2.6 21e 850e
R224D 97±2e 107±4e 13e 2.3 12e 550e
R224I 93±3e 102±5e 14e 2.0 12e 650e
R224K 86±2e 103±3e 10e 2.5 11e 550e
R224N 124±2e 99±7e 14e 2.4 15e 700e
L225A 102±3e 103±6e 13e 2.5 13e 550e
L225F 95±3e 110±6e 13e 2.0 11e 460e
L225H 84±3e 107±5e 12e 2.6 14e 700e
L225V 95±2e 91±3e 12e 2.3 12e 700e
K407H 80±2e 78±2e 13 3.4 13e 500e
K407R 93±3e 105±4e 12e 3.1 75e 550e
D458A 91±2 48±3 12f 3.3 520c 5200c
D458E 83±1 89±3 13 3.4 30 2200
V460L 83±4e 21±2e n.d. n.d. 130 9000
V460M 100±2e 16±1e 9f n.d. 53c 760c
E463Q 78±1 52±1 5f 2.3 34c 780c
E463T 78±2 35±2 11 2.8 8 800
n.d., not determined.
a 100% of complex I content corresponds to 1.25 µmol min−1 mg−1 NADH:HAR
oxidoreductase activity.
b Normalized for complex I content. Normalized NADH:DBQ oxidoreductase activity
of the parental strain was 0.58 µmol min−1 mg−1.
c Data from [13].
d Data from [17].
e Data from [21].
f Data from Kashani-Poor (unpublished data).
g Data from Grgic (unpublished data).
Table 2
Effects of point mutations introduced into the PSST subunit
Strain Complex I
contenta
Complex I
activityb
Apparent
Km of
DBQ
I50
C12E8 DQA Rotenone
% % µM µM nM
Parental 100±2c 100±3c 14c 3.0 13c 450c
V88L 94±4c 92±5c 15c 1.8 25c 500c
V88M 95±2c 56±3c 13c 1.5 32c 330c
M91C 114±2 31±4 11 1.3 500 15000
M91K 86±3 10±2 n.d. n.d. n.d. n.d.
n.d., not determined.
a 100% of complex I content corresponds to 1.25 µmol min−1 mg−1 NADH:HAR
oxidoreductase activity.
b Normalized for complex I content. Normalized NADH:DBQ oxidoreductase of the
parental strain was 0.6 µmol min−1 mg−1.
c Data from [21].
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the presence of a single ubiquinone reduction site within complex I,
thereby ruling out several hypothetical reaction schemes involving
a reversal of the ubiquinone cycle of the cytochrome bc1 complex
[11,12].
Several lines of evidence have indicated that a signiﬁcant part of the
ubiquinone reducing catalytic core of complex I is made up of the 49-
kDa and PSST subunits (the bovine heart complex I subunit nomen-
clature will be used throughout), which are evolutionary related to the
large and small subunits of water-soluble [NiFe] hydrogenases,
respectively [13]. A photoreactive derivative of the complex I inhibitor
pyridaben led to speciﬁc labelling of the PSST subunit in membranes
from Paracoccus denitriﬁcans and Thermus thermophilus [14]. A genetic
screen in Rhodobacter capsulatus for mutants showing resistance to the
inhibitor piericidin A yielded a missense mutation leading to substitu-
tion V407M (equivalent to V460M in Y. lipolytica) in the 49-kDa subunit
[15]. These observations have been corroborated in the following by the
generation and characterization of a number of site-directedmutations,
mainly in R. capsulatus [16] and in Y. lipolytica [13,17,18]. Signiﬁcantly,
exchanges of those residues that correspond to the hydrogenase [NiFe]
cluster ligands (D143, S146, V460, E463, Y. lipolytica numbering) or of
several nearby residues yielded resistance to rotenone, to DQA, or to
both inhibitors. On the basis of these ﬁndings we proposed that the
interface between the 49-kDa and PSST subunits has evolved fromwater-soluble [NiFe] hydrogenases to form a signiﬁcant part of the
ubiquinonebindingpocket of complex I [19]. This includes a cavity in the
49-kDa subunit that corresponds to the [NiFe] site in the large subunit of
the hydrogenase.
Recently, the structure of the peripheral arm of complex I from
T. thermophilus has been solved by X-ray crystallography [20]. It
conﬁrmed that this part of the complex contains all known redox
prosthetic groups, namely one FMN, non-covalently bound to the 51-
kDa subunit, and a chain of bi- and tetranuclear iron–sulfur clusters
that terminates in the ubiquinone reducing [Fe4S4] cluster N2 located
in the PSST subunit at the interface with the 49-kDa subunit. Taking
advantage of the X-ray structure of the peripheral arm of complex I
from T. thermophilus [20] we have mapped the ubiquinone binding
pocket in an extensive site-directed mutagenesis study and identiﬁed
a likely entry path for the substrate [21]. Using the same approach, we
have now focussed on the localization of the inhibitor binding sites. To
this end, we further expanded our collection of mutations around
iron–sulfur cluster N2 and analyzed the pattern of changes in afﬁnity
for the class I/type A inhibitor DQA, the class II/type B inhibitor
rotenone and the type C inhibitor n-alkyl-polyoxyethylene-ether
C12E8. Our results indicate that representatives from all three inhibitor
classes bind to deﬁned, but partially overlapping sites in a single, large
pocket. This strongly supports our earlier view derived from inhibitor
binding studies [5].
2. Materials and methods
Site-directed mutagenesis, small scale preparation of mitochondrial membranes,
measurement of NADH:HAR and dNADH:DBQ catalytic activities and preparation of
structural images were performed essentially as described in [21]. In brief, deletion
strains of Y. lipolytica lacking the NUCM gene which encodes the 49-kDa subunit or
lacking the NUKM gene which encodes the PSST subunit were complemented with
plasmid-borne site-directed mutant copies of the respective genes under the control of
their natural promoters. Strains complemented with unchanged gene copies are
referred to as parental strains. The n-alkyl-polyoxyethylene-ether detergent C12E8 was
purchased from Sigma-Aldrich GmbH, Munich and diluted as required for I50
determination in 20 mM Na+/Mops, pH 7.4, 50 mM NaCl, 2 mM KCN. Reactions were
started by the addition of 70 μM DBQ to a mixture that had been pre-incubated for at
least 30 s at 30 °C and contained 50 μg/ml mitochondrial membrane protein, 0.1 mM
dNADH in 20mMNa+/Mops, pH 7.4, 50mMNaCl, 2mMKCNand variable concentrations
of C12E8.
3. Results
For a more detailed structure/function analysis of the large ubi-
quinone reduction pocket around iron–sulfur cluster N2 of complex I,
it was necessary to deﬁne the inhibitor binding domains by site-
directedmutagenesis of the NUCM and NUKM genes, encoding the 49-
kDa and PSST subunits of the peripheral arm of complex I. We here
analyzed the I50 values for the inhibitors DQA (class I/type A),
rotenone (class II/type B) and C12E8 (type C) to cover all three major
Fig. 1. I50 values for C12E8 of parental strains and mutants in the C12E8 binding domain.
49-kDa parental and mutant strains are represented by black bars, PSST parental and
mutant strains by grey bars. Data are given as mean values±standard deviation. The
number of measurements with using two or more independent batches of mitochon-
drial membranes is given below the individual columns. All differences betweenmutant
and parental strain values were signiﬁcant on the pb0.001 level using two-tailed
Student's t-tests.
Fig. 2. Positions of mutations affecting the binding of C12E8. The structural model for the ubiq
the PSST and 49-kDa subunits is based on the X-ray structure of the peripheral arm of comp
The ﬁgure was prepared using the software package PyMol (version 0.99). Highlighted resid
match the Y. lipolytica sequence using the mutagenesis-wizard of the PyMol package. Am
hypersensitivity (I50≤2.0 µM), or in orangewhen resistance (I50≥4.5 µM) to C12E8 was observe
to be critical for catalytic activity is shown in white, residues in the 49-kDa subunit that cor
Cluster N2 in the PSST subunit is depicted as grey spheres. In A the approximate position of
hatched line. The three-stranded β-sheet at the N-terminus of the 49-kDa subunit is mark
interface of the 49-kDa and PSST subunits; C, D, View of the same region from the side of t
representation of the PSST and TYKY subunits and surface representation of the 49-kDa subu
sticks in B and D, and as spheres in C.
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here and in previous studies for a total of 34 exchanges at twelve
positions in the 49-kDa and two positions in the PSST subunit of the
yeast Y. lipolytica. The NADH:HAR oxidoreductase activities in mi-
tochondrial membranes from all mutants were near normal indicating
that assembly and stability of complex I was not severely affected by
any of the amino acid exchanges under study. As indicated in the
tables, 22 of these mutations at eleven positions have been analyzed
previously for effects on complex I assembly, ubiquinone reductase
activity and, in most cases, for sensitivity towards DQA and rotenone
[13,17,21]. These parameters were determined in this study for ano-
ther 12 mutations covering eight positions including one previously
not tested residue in each the 49-kDa subunit (F203) and in the PSST
subunit (M91). At each of the fourteen positions the effects of at least
two amino acid exchanges were analyzed. Mitochondrial membranes
from all mutants were tested for their sensitivity to C12E8 except 49-
kDa-R141A, 49-kDa-V460L, 49-kDa-V460M and PSST-M91K that
exhibited too low ubiquinone reductase activities. Tables 1 and 2
also show the apparent Km values for decylubiquinone of all mutantsuinone and inhibitor binding pocket of Y. lipolytica complex I, located at the interface of
lex I from T. thermophilus at 3.3 Å resolution (2FUG), but Y. lipolytica numbering is used.
ues that are not conserved between T. thermophilus and Y. lipolytica were exchanged to
ino acid positions are colour-coded in red when at least one exchange resulted in
d. For better orientation, residue Y144 in the 49-kDa subunit that was shownpreviously
respond to the [NiFe] cluster ligands of [NiFe] hydrogenases are shown in purple blue.
the inhibitor binding pocket with a narrow gorge and a wider opening is indicated by a
ed with β. A, B, Surface representation and cartoon representation of a view along the
he PSST subunit (rotated about 90° around the vertical axis relative to A, B). C, Cartoon
nit; D, Cartoon representation of all three subunits. Side chains of interest are shown as
Fig. 3. Positions of mutations affecting the binding of C12E8, DQA and rotenone. A, B, C, D. Same view as in Fig. 2. In A the approximate position of the inhibitor binding pocket with a
narrowgorge and awider opening is indicated by a hatched line. Amino acid positions are colour-coded in redwhen at least one exchange resulted in hypersensitivity (I50≤2.0 µM) to
C12E8. Light green denotes resistance to DQA and rotenone, blue denotes resistance to DQA only. Yellow was used to mark positions where effects were observed on the binding of
C12E8 and at least one additional inhibitor. Cluster N2 in the PSST subunit is depicted as grey spheres. See legend to Fig. 2 for additional details.
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reductase activity.
Altered I50 values for C12E8 were observed at six different positions
(Tables 1 and 2; Fig. 1). For these six mutants I50 values for C12E8 were
elevated or reduced by a factor of more than 1.5 compared to the
respective parental strain. Although the changes in inhibitory potency
for this inhibitorwere comparably small they proved highly signiﬁcant
(Fig. 1). In the 49-kDa subunit, mutations F203W, R224I and L225F led
to hypersensitivity to C12E8, while mutation F207H led to mild
resistance to C12E8 when compared to the parental strain. Other
mutations at positions R224 (D, N, K) and L225 (V, A, H) in the 49-kDa
subunit also displayed somewhat, yet not signiﬁcantly reduced I50
values for C12E8 (Table 1). In the PSST subunit, mutations V88M, V88L
and M91C resulted in signiﬁcant hypersensitivity to C12E8 when
compared to the parental strain. Among the mutants affected in C12E8
binding, most exhibited essentially unchanged normalized dNADH:
DBQ activities. Only in two mutants (V88M and M91C) dNADH:DBQ
activity was reduced by about 40 and 70%, respectively (Table 2).
When we highlighted the positions of the residues where mu-
tations had effects on C12E8 binding in the structure of the peripheral
arm of complex I from T. thermophilus, it became apparent that they
cluster in a conﬁned region right at the interface of the PSST and 49-
kDa subunits (red and orange in Fig. 2). This C12E8 binding domain is
close to cluster N2 in the PSST subunit and close to tyrosine 144 in the49-kDa subunit that was previously shown to be essential for catalytic
activity [21], but quite distinct from the former [NiFe] site of the
hydrogenases (in Fig. 2, the residues corresponding to the hydrogenase
[NiFe] site ligands are highlighted in purple blue).
Inprevious studies [13,17,21], a number of amino acid exchanges at the
interface of the 49-kDa and PSST subunits of Y. lipolytica complex I (49-
kDa:R141K, S146C, F207W,K407R,D458A,V460M;PSST:V88M)hadbeen
found to result in resistance to DQA and/or rotenone. In the present study,
when we tested these mutants for C12E8 binding, only PSST-V88M dis-
played effects on the I50 value for C12E8. However, when we examined
thosemutants that were affected in C12E8 binding, we found that a subset
of them also displayed resistance to DQA and/or rotenone, with in some
cases highly elevated I50 values (see Tables 1 and 2).
We alsohighlighted thepositions of the residues in the structure of the
peripheral arm of complex I from T. thermophilus where exchanges
resulted in resistance or hypersensitivity to the three inhibitors (Fig. 3).
Interestingly, the effects followed a consistent patternwithin the common
ubiquinone and inhibitor binding pocket of complex I. Many of the
mutations that affected the binding of DQA and/or rotenone (green and
blue in Fig. 3)map to the cavity in the 49-kDa subunit that corresponds to
the [NiFe] site of water-soluble [NiFe] hydrogenases. However, no effects
on the binding of C12E8 were found in this region.
Rather, exchanges that affected the I50 value for C12E8 (red and
yellow in Fig. 3) were found to cluster somewhat further away from
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(see Figs. 2B, D and 3B, D), where the crevice formed by the interface of
the 49-kDa and PSST subunits has turned into a rather narrow gorge
that curves to the left in Figs. 2A and 3A. The cluster of amino acids
where exchanges affected the I50 value for C12E8 extends up to the
upper rims of the two steep slopes. Within this cluster, those positions
where mutations simultaneously affected the binding of C12E8 and of
DQA and/or rotenone (F203 and F207 in the 49-kDa subunit, V88 and
M91 in the PSST subunit, highlighted in yellow in Fig. 3) form a group
that lies adjacent to the former [NiFe] site. In contrast, those positions
where mutations affected the binding of C12E8 alone (R224 and L225
in the 49-kDa subunit, highlighted in red in Fig. 3) were found at a
comparable distance from cluster N2, but deeper inside the protein
and further away from the former [NiFe] site.
4. Discussion
The ubiquinone and inhibitor binding pocket of complex I offer
numerous potential binding sites for the large number of amphipathic
compounds known to interact with this respiratory chain enzyme. To
better deﬁne where the different classes of these compounds bind in
this domain at the interface of the 49-kDa and PSST subunits, we have
performed an extensive site-directed mutagenesis study using our
model system, the obligate aerobic yeast Y. lipolytica. Extending a
previous study that identiﬁed a number of residues required for
catalytic activity [21], we here focussed on the inhibitor binding
properties of complex I.
Using direct competition assays we had shown previously that
representatives of the various inhibitor types or classes bind todistinct,
but overlapping regions within a common inhibitor binding domain
[5]. The results from our present mutagenesis study strongly support
this notion and togetherwith the now available structural information
[20] provide additional clues on the structure/function relationships
involved. The large binding pocket around iron–sulfur cluster N2 of
complex I is formed by domains of the 49-kDa subunit and the PSST
subunit (Figs. 2A and 3A). Its rather wide opening narrows to a gorge
deﬁned by two hydrophobic residues of the 49-kDa subunit (F203 and
F207) and two hydrophobic residues of the PSST subunit (V88 and
M91). Remarkably,mutagenesis of these four residues (yellow in Fig. 3)
affected the afﬁnity for all three types of inhibitors. Below this rim, in
either direction along the gorge, the effects of mutagenesis could be
differentiated by the inhibitors tested. On one side (red in Fig. 3)
mutations caused hypersensitivity to C12E8 (type C). Note that the
mutations of V88 only resulted in mild resistance to DQA and a slight
hypersensitivity to rotenone, but clear hypersensitivity to C12E8. This is
consistent with its position only 7–8 Å away from R224 and L225. On
the other side mutagenesis of a number of residues lining the major
cavity of the pocket that corresponds to the former [NiFe] site of water-
soluble [NiFe] hydrogenases led to in some cases pronounced
resistance to DQA (class I/type A) and rotenone (class II/type B). This
suggested that the binding regions for these two types of inhibi-
tors largely overlap. However, deep into the pocket two positions
(K407 and E463; blue in Fig. 3) were found where mutations led to
signiﬁcant resistance to DQA alone. On the opposite, upper side of
the cavity however, mutation M188C resulted in a 5-fold increase
in the I50 value for rotenone, but only slightly affected DQA binding.
This seems to indicate that DQA penetrates deeper into the ex-[NiFe]
site cavity than rotenone. Interestingly, the only exchange (F207H;
orange in Fig. 2) that resulted in C12E8 resistance rather than hy-
persensitivity was found in the region affecting all three types of
inhibitors.
The recently identiﬁed ubiquinone entry pathway leads from the
three-stranded β-sheet at the N-terminus of the 49-kDa subunit
(bottom right in Figs. 2B and 3B) through the large opening of the
binding pocket to Y144 of the 49-kDa subunit that resides right next to
iron–sulfur cluster N2 in the PSST subunit [21] and is part of the cavitycomprising the inhibitor binding regions (Fig. 2). Extending this
pathway beyond cluster N2 leads to a region of the 49-kDa subunit
where mutations caused hypersensitivity to C12E8, but did not affect
catalytic activity (Table 1).
It seems likely that the binding regions for the different types of
inhibitors overlap with the proposed entry pathway for ubiquinone.
However, this could not be tested experimentally because most of the
residues that deﬁne this pathway cannot be exchangedwithout severe
reductions in ubiquinone reductase activity [21]. None of the
mutations studied here caused a pronounced increase in the apparent
Km value for decylubiquinone. On the other hand, we have observed in
this and in earlier studies that mutations that exhibit marked inhibitor
resistance tend to have lower ubiquinone reductase activities and that
mutations with reduced ubiquinone reductase activities tend to have
lowered apparent Km values for decylubiquinone. The latter phenom-
enon, which is poorly understood at present, may indicate that the
interaction with decylubiquinone is to a certain extent under
diffusional control. In summary, while the results of the current
study do not allow to precisely deﬁne the ubiquinone binding site of
complex I, they suggest that most of the residues forming the large
cavity that corresponds to the former [NiFe] site are not directly
involved in productive ubiquinone binding.
At present, our studies on the binding of substrates and inhibitors
to complex I are limited to the characterization of mutants that alter
ubiquinone kinetics and the afﬁnity for hydrophobic inhibitors.
Eventually co-crystallization of holo-complex I with substrates and
inhibitors will be necessary to understand these data in detail and
precisely deﬁne the inhibitor and substrate binding sites.Acknowledgements
We would like to thank Gudrun Beyer for the excellent technical
assistance. This work was supported by the Deutsche Forschungsge-
meinschaft, Sonderforschungsbereich 472, Project P2 and the Cluster
of Excellence “Macromolecular Complexes” at the Goethe University
Frankfurt (DFG Project EXC 115).References
[1] U. Brandt, Energy converting NADH:quinone oxidoreductases, Annu. Rev. Biochem.
75 (2006) 69–92.
[2] M. Radermacher, T. Ruiz, T. Clason, S. Benjamin, U. Brandt, V. Zickermann, The
three-dimensional structure of complex I from Yarrowia lipolytica: a highly
dynamic enzyme, J. Struct. Biol. 154 (2006) 269–279.
[3] M. Degli Esposti, Inhibitors of NADH-ubiquinone reductase: an overview, Biochim.
Biophys. Acta 1364 (1998) 222–235.
[4] A.V. Ushakova, V.G. Grivennikova, T. Ohnishi, A.D. Vinogradov, Triton X-100 as a
speciﬁc inhibitor of the mammalian NADH-ubiquinone oxidoreductase (complex I),
Biochim. Biophys. Acta 1409 (1999) 143–153.
[5] J.G. Okun, P. Lümmen, U. Brandt, Three classes of inhibitors share a common
binding domain in mitochondrial complex I (NADH:ubiquinone oxidoreductase),
J. Biol. Chem. 274 (1999) 2625–2630.
[6] J.G. Okun, V. Zickermann, U. Brandt, Properties of the common inhibitor binding
domain in mitochondrial NADH-dehydrogenase (complex I), Biochem. Soc. Trans.
27 (1999) 596–601.
[7] J.G. Okun, V. Zickermann, K. Zwicker, H. Schägger, U. Brandt, Binding of detergents
and inhibitors to bovine complex I — a novel puriﬁcation procedure of bovine
complex I retaining full inhibitor sensitivity, Biochim. Biophys. Acta 1459 (2000)
77–87.
[8] T. Friedrich, P. van Heek, H. Leif, T. Ohnishi, E. Forche, B. Kunze, R. Jansen, W.
Trowitzsch-Kienast, G. Höﬂe, H.X. Reichenbach, H. Weiss, Two binding sites of
inhibitors in NADH:ubiquinone oxidoreductase (complex I). — relationship of one
site with the ubiquinone-binding site of bacterial glucose:ubiquinone oxidor-
eductase. Eur. J. Biochem. 219 (1994) 691–698.
[9] M. Degli Esposti, A.X. Ghelli, The mechanism of proton and electron transport in
mitochondrial complex I. Biochim. Biophys. Acta 1187 (1994) 116–120.
[10] T. Satoh, H. Miyoshi, K. Sakamoto, H. Iwamura, Comparison of the inhibitory action
of synthetic capsaicin analogues with various NADH-ubiquinone oxidoreductases,
Biochim. Biophys. Acta 1273 (1996) 21–30.
[11] U. Brandt, Proton-translocation by membrane-bound NADH:ubiquinone-oxidor-
eductase (complex I) through redox-gated ligand conduction, Biochim. Biophys.
Acta 1318 (1997) 79–91.
665U. Fendel et al. / Biochimica et Biophysica Acta 1777 (2008) 660–665[12] P.L. Dutton, C.C. Moser, V.D. Sled, F. Daldal, T. Ohnishi, A reductant-induced
oxidation mechanism for complex I, Biochim. Biophys. Acta 1364 (1998) 245–257.
[13] N. Kashani-Poor, K. Zwicker, S. Kerscher, U. Brandt, A central functional role for the
49-kDa subunit within the catalytic core of mitochondrial complex I, J. Biol. Chem.
276 (2001) 24082–24087.
[14] F. Schuler, T. Yano, S. Di Bernardo, T. Yagi, V. Yankovskaya, T.P. Singer, J.E. Casida,
NADH-quinone oxidoreductase: PSST subunit couples electron transfer from
iron–sulfur cluster N2 to quinone, Proc. Natl. Acad. Sci. U. S. A. 96 (1999)
4149–4153.
[15] E. Darrouzet, A. Dupuis, Genetic evidence for the existence of two quinone related
inhibitor binding sites in NADH-CoQ reductase, Biochim. Biophys. Acta 1319 (1997)
1–4.
[16] E. Darrouzet, J.P. Issartel, J. Lunardi, A. Dupuis, The 49-kDa subunit of NADH-
ubiquinone oxidoreductase (complex I) is involved in the binding of piericidin and
rotenone, two quinone-related inhibitors, FEBS Lett. 431 (1998) 34–38.
[17] L. Grgic, K. Zwicker, N. Kashani-Poor, S. Kerscher, U. Brandt, Functional signiﬁcanceof conserved histidines and arginines in the 49 kDa subunit of mitochondrial
complex I, J. Biol. Chem. 279 (2004) 21193–21199.
[18] S. Kerscher, V. Zickermann, K. Zwicker, U. Brandt, Insights into the mechanism of
mitochondrial complex I from its distant relatives, the [NiFe] hydrogenases, in: M.
Wikstrom (Ed.), Biophysical and Structural Aspects of Bioenergetics, RSC Publish-
ing, Cambridge, 2005, pp. 156–184.
[19] S. Kerscher, N. Kashani-Poor, K. Zwicker, V. Zickermann, U. Brandt, Exploring the
catalytic core of complex I by Yarrowia lipolytica yeast genetics, J. Bioenerg.
Biomembr. 33 (2001) 187–196.
[20] L.A. Sazanov, P. Hinchliffe, Structure of the hydrophilic domain of respiratory
complex I from Thermus thermophilus, Science 311 (2006) 1430–1436.
[21] M.A. Tocilescu, U. Fendel, K. Zwicker, S. Kerscher, U. Brandt, Exploring the ubiquinone
binding cavity of respiratory complex I, J. Biol. Chem. 282 (2007) 29514–29520.
[22] A. Abdrakhmanova, V. Zickermann, M. Bostina, M. Radermacher, H. Schägger, S.
Kerscher, U. Brandt, Subunit composition of mitochondrial complex I from the
yeast Yarrowia lipolytica, Biochim. Biophys. Acta 1658 (2004) 148–156.
